Multiple sclerosis: A practical overview for clinicians

British Medical Bulletin

Volumn 95, Issue 1, 2010, Pages 79-104

  Rejdak, Konrad ^a   Jackson, Samuel ^b   Giovannoni, Gavin ^b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

clinical practice; multiple sclerosis; recent advances

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CARBAMAZEPINE; CLADRIBINE; CYCLOPHOSPHAMIDE; DACLIZUMAB; EXTAVIA; FUMARIC ACID DIMETHYL ESTER; GABAPENTIN; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON BETA SERINE; INTERLEUKIN 10; INTERLEUKIN 4; LAMOTRIGINE; LAQUINIMOD; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; OCRELIZUMAB; PHENYTOIN; RITUXIMAB; TERIFLUNOMIDE; TOPIRAMATE; TRANSFORMING GROWTH FACTOR BETA; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERY LATE ACTIVATION ANTIGEN 4;

AUTOIMMUNITY; CEREBROSPINAL FLUID ANALYSIS; CHEST TIGHTNESS; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL RESEARCH; DIETARY FIBER; DRUG CHOICE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; FLU LIKE SYNDROME; FLUSHING; FOLLOW UP; GENETIC RISK; HEART DISEASE; HISTOPATHOLOGY; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INJECTION SITE ATROPHY; INJECTION SITE ERYTHEMA; INJECTION SITE NECROSIS; INJECTION SITE PAIN; INJECTION SITE SWELLING; LEUKEMIA; LIPOATROPHY; LIVER FUNCTION TEST; LYMPHOCYTOPENIA; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PAIN; PLASMAPHERESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RELAPSE; REVIEW; SCHILDER DISEASE; SIDE EFFECT; SKIN DISEASE; SPASTICITY;

ADULT; AUTOIMMUNE DISEASES; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MULTIPLE SCLEROSIS; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 77956236570     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldq017     Document Type: Review

References (78)

1. Lucchinetti C, Bruck W, Parisi J et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-717
2. Compston A, Coles A. Multiple sclerosis. Lancet 2002;359:1221-1231
3. Coles AJ, Cox A, Le Page E et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006;253:98-108.
4. Maggs FG, Palace J. The pathogenesis of multiple sclerosis: is it really a primary inflammatory process? Mult Scler 2004;10:326-329
5. Poser CM. Viking voyages: the origin of multiple sclerosis? An essay in medical history. Acta Neurol Scand 1995;161(Suppl.):11-22.
6. Dyment DA, Ebers GC, Sadovnick AD. Genetics of multiple sclerosis. Lancet Neurol 2004;3:104-110
7. International Multiple Sclerosis Genetics Consortium, Hafler DA, Compston A et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007;357:851-862
8. Kantarci OH, de Andrade M, Weinshenker BG. Identifying disease modifying genes in multiple sclerosis. J Neuroimmunol 2002;123:144-159
9. Colhoun HM, McKeigue PM, Smith GD. Problems of reporting genetic associations with complex outcomes. Lancet 2003;361:865-872
10. Kurtzke JF. Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev 1993;6:382-427.
11. Ascherio A, Munger KL, Lennette ET et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 2001;286:3083-3088
12. Levin LI, Munger KL, Rubertone MV et al. Multiple sclerosis and Epstein-Barr virus. JAMA 2003;289:1533-1536
13. Pender MP. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol 2003;24:584-588
14. Lang HL, Jacobsen H, Ikemizu S et al. A functional and structural basis for TCR cross- reactivity in multiple sclerosis. Nat Immunol 2002;3:940-943
15. Swanborg RH, Whittum-Hudson JA, Hudson AP. Infectious agents and multiple sclerosis- are Chlamydia pneumoniae and human herpes virus 6 involved? J Neuroimmunol 2003;136:1-8.
16. Pierrot-Deseilligny C. Clinical implications of a possible role of vitamin D in multiple sclerosis. J Neurol 2009;256:1468-1479
17. Correale J, Ysrraelit MC, Gaitan MI. Immunomodulatory effects of vitamin D in multiple sclerosis. Brain 2009;132:1146-1160
18. Lassmann H, Raine CS, Antel J et al. Immunopathology of multiple sclerosis: report on an international meeting held at the Institute of Neurology of the University of Vienna. J Neuroimmunol 1998;86:213-217
19. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004;55:458-468
20. Breij EC, Brink BP, Veerhuis R et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol 2008;63:16-25.
21. Keegan M, Konig E, Bitsch A et al. Multiple sclerosis pathological subtype predicts response to therapeutic plasma exchange. Neurology 2004;62(Suppl. 5):259-260
22. Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 2003;206:165-171
23. Kutzelnigg A, Lassmann H. Cortical demyelination in multiple sclerosis: a substrate for cognitive deficits? J Neurol Sci 2006;245:123-126
24. Peterson JW, Bo L, Mork S et al. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001;50:389-400.
25. Bø L, Vedeler CA, Nyland H et al. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler 2003;9:323-331
26. Serafini B, Rosicarelli B, Franciotta D et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007;204:2899-2912
27. Willis SN, Stadelmann C, Rodig SJ et al. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain 2009;132:3318-3328
28. Salvetti M, Giovannoni G, Aloisi F. Epstein-Barr virus and multiple sclerosis. Curr Opin Neurol 2009;22:201-216
29. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-911
30. Weinshenker BG, Fujihara K, Pittock SJ et al. The Asian optico-spinal form of multiple sclerosis is the same entity as neuromyelitis optica in Caucasians: insights from a novel serum marker. Neurology 2004;62(Suppl. 5):480-481
31. Fisniku LK, Brex PA, Altmann DR et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131:808-817
32. Thompson AJ, Polman CH, Miller DH et al. Primary progressive multiple sclerosis. Brain 1997;120:1085-1096
33. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452
34. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993;116:117-134
35. Confavreux C, Vukusic S, Moreau T et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430-1438
36. McAlpine D. The benign form of multiple sclerosis. A study based on 241 cases seen within three years of onset and followed up until the tenth year or more of the disease. Brain 1961;84:186-203.
37. Kremenchutzky M, Cottrell D, Rice G et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain 1999;122:1941-1950.
38. Pittock SJ, McClelland RL, Mayr WT et al. Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann Neurol 2004;56:303-336
39. Engell T. A clinico-pathoanatomical study of multiple sclerosis diagnosis. Acta Neurol Scand 1988;78:39-44.
40. Masterman T, Hillert J. The telltale scan: APOE epsilon4 in multiple sclerosis. Lancet Neurol 2004;3:331.
41. Runmarker B, Andersen O. Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain 1995;118:253-261
42. Vukusic S, Hutchinson M, Hours M et al. The Pregnancy In Multiple Sclerosis Group; Pregnancy In Multiple Sclerosis Group. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 2004;127:1353-1360
43. DeStefano F, Verstraeten T, Jackson LA et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol 2003;60:504-549
44. Mohr DC, Hart SL, Julian L et al. Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. BMJ 2004;328:731.
45. Bronnum-Hansen H, Koch-Henriksen N, Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 2004;127:844-850
46. Lennon VA, Kryzer TJ, Pittock SJ et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin 4 water channel. J Exp Med 2005;202:473-477
47. Weinshenker BG, OBrien PC, Petterson TM et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999;46:878-886
48. Jacob A, Weinshenker BG, Violich I et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008;65:1443-1448
49. Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231
50. McDonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127
51. Polman CH, Reingold SC, Edan G et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58:840-846
52. Thompson AJ, Montalban X, Barkhof F et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 2000;47:831-835
53. Miller DH, Grossman RI, Reingold SC et al. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998;121:3-24.
54. Bielekova B, Martin R. Development of biomarkers in multiple sclerosis. Brain 2004;127:1463-1478
55. National Insitute of Clinical Excellence (NICE). Multiple Sclerosis-Beta Interferon and Glatiramer Acetate, 2002; Guidance No. 32: http://www.nice.org. uk/page.aspx?o=27588 (10 August 2009, date last accessed).
56. Department of Health, HSC 2002/004. Cost Effective Provision of Disease Modifying Therapies for People with Multiple Sclerosis, 2002. http://www.dh.gov.uk/PublicationsAndStatistics/LettersAndCirculars/ HealthServiceCirculars/HealthServiceCircularsArticle/fs/en?C0NTENT-ID= 4004332&chk=HmUDKa (10 August 2009, date last accessed).
57. Association of British Neurologists. Guidelines for the use of beta interferons and glatiramer acetate in multiple sclerosis, 2001.
58. Department of Health. HSC 2002/004. Cost Effective Provision ofDisease Modifying Therapies for People with Multiple Sclerosis. http://www.dh.gov.uk/en/ PublicationsAndStatistics/LettersAndCirculars/HealthServiceCirculars/DH-4004332 (10 August 2009, date last accessed).
59. Goodin DS, Frohman EM, Garmany GP et al. Therapeutics and technology assessment subcommittee of the American academy of neurology and the MS Council for Clinical Practice Guidelines. Disease modifying therapies in multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169-178
60. Panitch H, Goodin DS, Francis G et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 2002;59:1496-1506
61. Durelli L, Verdun E, Barbero P et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study INCOMIN). Lancet 2002;359:1453-1460
62. Giovannoni G, Munschauer FE 3rd, Deisenhammer F. Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002;73:465-469
63. Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicentre, double-blind placebo-controlled trial. Neurology 1995;45:1268-1276
64. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001;49:2902-2997
65. Wolinsky JS, Narayana PA, OConnor P et al. PROMiSe Trial Study Group. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007;61:14-24.
66. Mikol DD, Barkhof F, Chang P et al. REGARD study group. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008;7:903-914
67. Connor P, Filippi M, Arnason B et al. BEYOND Study Group. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009;8:889-897
68. Edan G, Miller D, Clanet M et al. Therapeutic effect of mitoxantrone combined with methyl-prednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997;62:112-118
69. Hartung HP, Gonsette R, Konig N et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018-2025
70. Polman CH, OConnor PW, Havrdova E et al. AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
71. Rudick RA, Stuart WH, Calabresi PA et al., SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-923
72. Bielekova B, Howard T, Packer AN et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 2009;66:483-489
73. Hauser SL, Waubant E, Arnold DL et al. HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-688
74. CAMMS223 Trial Investigators, Coles AJ, Compston DA et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359:1786-1801
75. DeAngelis T, Lublin F. Multiple sclerosis: new treatment trials and emerging therapeutic targets. Curr Opin Neurol 2008;21:261-271
76. Giovannoni G, Comi G, Cook S et al., CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010;362:416-426
77. Kappos L, Radue EW, OConnor P et al., FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
78. National Multiple Sclerosis Society Website. Research: Clinical Trials. http://www.nationalmssociety.org/research/clinical-trials/index.aspx (10 August 2009, date last accessed).